Bio-Techne (TECH) Other Non-Current Liabilities (2014 - 2026)
Bio-Techne (TECH) posted quarterly Other Non-Current Liabilities of $21.7 million for Q1 2026, up 38.4% year-over-year from $15.7 million in Q1 2025, and down 6.11% quarter-over-quarter from $23.1 million in Q4 2025.
Analysis
Bio-Techne (TECH) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Bio-Techne's Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $21.7 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 38.4% year-over-year to $21.7 million; the TTM figure through Mar 2026 stood at $21.7 million (up 38.4% YoY), while the FY2025 annual figure was $27.1 million, up 105.84% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $21.7 million, down from $23.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $27.1 million in Q2 2025, with the low at $5.0 million in Q2 2022.
- The 5-year median for Other Non-Current Liabilities is $12.8 million (2022), against an average of $15.1 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 72.68% in 2022, then jumped 118.38% in 2023.
- Bio-Techne's Other Non-Current Liabilities stood at $11.3 million in 2022, then jumped by 53.15% to $17.4 million in 2023, then slumped by 34.7% to $11.3 million in 2024, then jumped by 103.56% to $23.1 million in 2025, then slipped by 6.11% to $21.7 million in 2026.
- Business Quant data shows TECH's Other Non-Current Liabilities at $21.7 million in Q1 2026, $23.1 million in Q4 2025, and $23.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Bio-Techne | 11.29 Bn | 11.03 Bn | 211.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.35 Mn |
| Mar 31, 2026 | 21.67 Mn |
| Dec 31, 2025 | 23.08 Mn |
| Sep 30, 2025 | 23.81 Mn |
| Jun 30, 2025 | 27.08 Mn |
| Mar 31, 2025 | 15.66 Mn |
| Dec 31, 2024 | 11.34 Mn |
| Sep 30, 2024 | 19.79 Mn |
| Jun 30, 2024 | 13.16 Mn |
| Mar 31, 2024 | 11.56 Mn |
| Dec 31, 2023 | 17.36 Mn |
| Sep 30, 2023 | 9.39 Mn |
| Jun 30, 2023 | 10.92 Mn |
| Mar 31, 2023 | 10.97 Mn |
| Dec 31, 2022 | 11.34 Mn |
| Sep 30, 2022 | 11.50 Mn |
| Jun 30, 2022 | 12.24 Mn |
| Mar 31, 2022 | 12.77 Mn |
| Dec 31, 2021 | 11.75 Mn |
| Sep 30, 2021 | 20.05 Mn |